Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
Wensing AM, van de Vijver DA, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA; SPREAD Programme. Wensing AM, et al. Among authors: macrae e. J Infect Dis. 2005 Sep 15;192(6):958-66. doi: 10.1086/432916. Epub 2005 Aug 15. J Infect Dis. 2005. PMID: 16107947
The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
van de Vijver DA, Wensing AM, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Costagliola D, De Luca A, Derdelinckx I, Grossman Z, Hamouda O, Hatzakis A, Hemmer R, Hoepelman A, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, MacRae E, Maljkovic I, de Mendoza C, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Paraskevis D, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen M, Schmit JC, Schneider F, Schuurman R, Soriano V, Stanczak G, Stanojevic M, Vandamme AM, Van Laethem K, Violin M, Wilbe K, Yerly S, Zazzi M, Boucher CA. van de Vijver DA, et al. Among authors: macrae e. J Acquir Immune Defic Syndr. 2006 Mar;41(3):352-60. doi: 10.1097/01.qai.0000209899.05126.e4. J Acquir Immune Defic Syndr. 2006. PMID: 16540937
HIV-1 drug-resistance patterns among patients on failing treatment in a large number of European countries.
van de Vijver DA, Wensing AM, Åsjö B, Bruckova M, Jorgensen LB, Camacho R, Horban A, Linka M, Lazanas M, Loveday C, MacRae E, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Ruiz L, Schmit JC, Stanczak G, Stanojevic M, Vandamme AM, Vercauteren J, Zazzi M, Bacheler L, Lecocq P, Villacian J, Boucher CA. van de Vijver DA, et al. Among authors: macrae e. Acta Dermatovenerol Alp Pannonica Adriat. 2010 Dec;19(4):3-9. Acta Dermatovenerol Alp Pannonica Adriat. 2010. PMID: 21390473 Free article.
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.
Paraskevis D, Pybus O, Magiorkinis G, Hatzakis A, Wensing AM, van de Vijver DA, Albert J, Angarano G, Asjö B, Balotta C, Boeri E, Camacho R, Chaix ML, Coughlan S, Costagliola D, De Luca A, de Mendoza C, Derdelinckx I, Grossman Z, Hamouda O, Hoepelman I, Horban A, Korn K, Kücherer C, Leitner T, Loveday C, Macrae E, Maljkovic-Berry I, Meyer L, Nielsen C, Op de Coul EL, Ormaasen V, Perrin L, Puchhammer-Stöckl E, Ruiz L, Salminen MO, Schmit JC, Schuurman R, Soriano V, Stanczak J, Stanojevic M, Struck D, Van Laethem K, Violin M, Yerly S, Zazzi M, Boucher CA, Vandamme AM; SPREAD Programme. Paraskevis D, et al. Among authors: macrae e. Retrovirology. 2009 May 20;6:49. doi: 10.1186/1742-4690-6-49. Retrovirology. 2009. PMID: 19457244 Free PMC article.
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson WE 3rd. Quiroga D, et al. Among authors: macrae e. Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189. Cancer Control. 2024. PMID: 38797949 Free PMC article. Clinical Trial.
Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB, Ankolekar S, Appireddy R, Arenillas JF, Assis Z, Bailey P, Barber PA, Bazan R, Buck BH, Butcher KS, Camden MC, Campbell BCV, Casaubon LK, Catanese L, Chatterjee K, Choi PMC, Clarke B, Dowlatshahi D, Ferrari J, Field TS, Ganesh A, Ghia D, Goyal M, Greisenegger S, Halse O, Horn M, Hunter G, Imoukhuede O, Kelly PJ, Kennedy J, Kenney C, Kleinig TJ, Krishnan K, Lima F, Mandzia JL, Marko M, Martins SO, Medvedev G, Menon BK, Mishra SM, Molina C, Moussaddy A, Muir KW, Parsons MW, Penn AMW, Pille A, Pontes-Neto OM, Roffe C, Serena J, Simister R, Singh N, Spratt N, Strbian D, Tham CH, Wiggam MI, Williams DJ, Willmot MR, Wu T, Yu AYX, Zachariah G, Zafar A, Zerna C, Hill MD; TEMPO-2 investigators. Coutts SB, et al. Lancet. 2024 Jun 15;403(10444):2597-2605. doi: 10.1016/S0140-6736(24)00921-8. Epub 2024 May 17. Lancet. 2024. PMID: 38768626 Clinical Trial.
Study on impact of robotic-assisted orthopaedic industrial noise (SIREN).
Goffin J, MacRae E, Farrow L, Whittaker D, Dixon J, Rankin I, Krishnamurthy A, Stevenson I. Goffin J, et al. Among authors: macrae e. Arch Orthop Trauma Surg. 2024 May;144(5):2413-2420. doi: 10.1007/s00402-024-05303-8. Epub 2024 Apr 5. Arch Orthop Trauma Surg. 2024. PMID: 38578310 Free PMC article.
Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
Burstein HJ, DeMichele A, Fallowfield L, Somerfield MR, Henry NL; Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels; Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels for the Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panel. Burstein HJ, et al. J Clin Oncol. 2024 Apr 20;42(12):1450-1453. doi: 10.1200/JCO.24.00248. Epub 2024 Mar 13. J Clin Oncol. 2024. PMID: 38478799
107 results